Upfront Briefing
Dupixent picked up a U.S. label in children aged 2–11 with uncontrolled chronic spontaneous urticaria — an incremental pediatric expansion that keeps one of biopharma’s biggest franchises compounding.
Elsewhere, Inhibrx moved into the takeover spotlight with Reuters reporting broad interest in its oncology spin-off assets, while Roche showed again how healthy underlying demand can still look messy once Swiss-franc translation hits the print.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,137.9 |
+1.0% |
+3.2% |
| Nasdaq 100 |
26,937.3 |
+1.7% |
+5.6% |
| Russell 2000 |
2,785.4 |
+0.7% |
+2.4% |
| Healthcare (XLV) |
146.4 |
+0.3% |
(7.1%) |
| Biotech (XBI) |
137.3 |
+0.7% |
+4.4% |
| Nasdaq Biotech (NBI) |
6,052.0 |
+0.1% |
+0.5% |
| Clinical Trials (BBC) |
47.4 |
+0.6% |
+7.9% |
|
- Risk-on tape returned after Trump said the U.S.–Iran ceasefire would continue indefinitely, lifting broad sentiment and sending both the S&P 500 and Nasdaq complex to fresh record closes.
- Biotech kept pace with the broader beta bid rather than lagging it: XBI matched the Russell 2000 on the day, while XLV trailed, suggesting the move was driven more by improving risk appetite than by a fresh defensive-healthcare rotation.
- Market data: U.S. close Wed 22-Apr-2026.
The Big 3
|
1
|
Dupixent wins US approval for young children with CSU
|
- Dupixent (dupilumab) was approved in the U.S. for children aged 2–11 with uncontrolled chronic spontaneous urticaria, expanding the franchise below the prior 12+ population as the first biologic in this setting.
- Why it matters: This is a lifecycle-extension win for an already dominant franchise, not a new peak-sales reset. The investor read-through is that Sanofi/Regeneron keep widening Dupixent’s treated base, now pushing the CSU label down into ages 2–11 while Sanofi’s Q1 print also reinforced how central Dupixent remains to group growth. That supports franchise durability and keeps the brand compounding across adjacent type 2 inflammatory markets.
- Source: PR
- More: PR
|
|
2
|
Roche posts Q1 2026 sales up 6% CER, down 5% in CHF
|
- Roche reported Q1 2026 sales growth of +6% at constant exchange rates, but -5% in CHF due to Swiss franc appreciation. The update highlights the FX impact on reported results.
- Why it matters: The key signal is not the reported -5% in CHF, but the underlying +6% CER growth, +9% growth in USD and an unchanged full-year outlook. Roche also said five products — Xolair, Phesgo, Hemlibra, Vabysmo and Ocrevus — together delivered CHF 5.3B of sales, up 14% CER, which strengthens the case that this was a translation issue rather than a demand problem. For investors, that matters because the headline can look soft even when the operating engine is tracking roughly in line with expectations.
-
Source:
PR
-
More:
PR
|
| 3 | Inhibrx enters the bid-watch zone as oncology assets draw broad interest |
- Reuters reported that multiple pharma groups — including Merck, Merck KGaA, Ono, Lilly, AstraZeneca, Pfizer and J&J — are showing interest in Inhibrx Biosciences’ planned oncology spin-off, which would house INBRX-106 and ozekibart/INBRX-109, a two-asset package that could be worth more than $9B if trials succeed.
- Why it matters: This is the day’s real strategic tape. The read-through is not just bid speculation around one asset, but validation that Inhibrx has recreated a familiar playbook after its 2024 Sanofi transaction: separate the oncology optionality, create a cleaner deal perimeter and let multiple large-cap buyers compete around differentiated immuno-oncology assets. For investors, the combination of a sharp stock reaction and a reported >$9B success-case value makes this the more meaningful sector signal of the day.
- Source: Reuters
|
Everything Else that broke
- FDA accepts Roche’s sBLA for Gazyva/Gazyvaro in systemic lupus erythematosus; decision expected by December 2026. — PR
- Ipsen posts Q1 2026 sales and reaffirms full-year guidance. — PR
- Sanofi Q1 2026: double-digit sales and business EPS growth — underlining how central Dupixent remains to the story on the same day as its pediatric CSU approval. — PR
- MINJUVI wins Australia approval in relapsed/refractory FL. — PR
- Orion starts TEADCO Phase 1b/2 basket trial for ODM-212. — PR
- OSE to present Tedopi Phase 2 topline data in ovarian cancer. — PR
- PulseSight completes Phase 1 LPLV for PST-611 in dry AMD/GA. — PR
- WuXi Biologics gets South Korea MFDS GMP for bispecifics. — PR
- Santhera names Orlando Oliveira CEO. — PR
- Neurosterix aims to complete NTX-253 Phase 1 in Q2 2026. — PR
- Greenwich LifeSciences gets Nasdaq notice over late 10-K. — PR
- Prestige Biopharma IDC files patent for SC delivery platform IDC224. — PR
- BioCentury: Reese to retire after two decades at Amgen. — BioCentury
- Vitrolife Q1 2026: strong growth in Consumables and Tech. — PR
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
- Amneal to acquire Kashiv BioSciences in a cash-and-stock deal worth up to $1.1B, building a fully integrated biosimilars platform. — Reuters
- Exicure and Adbiotech outlined a preliminary co-development framework around Burixafor (GPC-100), with economics, IP and commercialization to be set in a later definitive agreement. — PR
- PrecisionBiotics and Biocodex sign new partnership agreement. — PR
VC / Private Financings
- No notable core biotech VC / private financings surfaced in the last 24 hours.
IPOs / Follow-Ons
- No notable IPOs / Follow-Ons in the last 24 hours.
Academic Corner
- Ketamine or Etomidate for Tracheal Intubation of Critically Ill Adults. — NEJM
- Tucidinostat Plus R-CHOP vs R-CHOP in MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma. — JAMA
|
